Company: CERO
Filing Date: 2025-05-27
Form Type: POS AM
Source: 0001213900-25-047469
Chunk: 397

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-27
Form: POS AM
Chunk 397
---
625Series A Preferred Warrants were exercised into 625shares of Series A Preferred Stock for gross cash proceeds of $ 500,000. On January 6, 2025, the Company issued warrants to purchase an aggregate of 163,853shares of Common Stock to a certain investor affiliated with each other to induce investors to exercise their Series A Preferred Warrants for cash (the “January 2025 Common Warrants”). The January 2025 Common Warrants are initially exercisable for cash at an initial exercise price equal to $ 5.82(as adjusted for stock splits, stock dividends, stock combinations, recapitalizations and similar events). The January 2025 Common Warrants are exercisable beginning six months after the issuance date (the “Initial Exercisability Date”) and expiring on the third anniversary of the Initial Exercisability Date. The January 2025 Common Warrants require “buy-in” payments to be made by us for failure to deliver any shares of Common Stock issuable upon exercise. If at the time of exercise of the January 2025 Common Warrants, there is no effective registration statement registering the shares of the Common Stock underlying the January 2025 Common Warrants, such warrants may be exercised on a cashless basis pursuant to their terms During the period from January 1, 2025 to April 10, 2025, 1,098shares of Series A Preferred Stock were converted into 288,832shares of Common Stock. The conversion ratio was based on the Series A Certificate of Designations and reflected the applicable Alternate Conversion Price. During the period from January 1, 2025 to April 10, 2025, 75shares of Series B Preferred Stock were converted into 50,001shares of Common Stock. The conversion ratio was based on the Series B Certificate of Designations and reflected the applicable Alternate Conversion Price. F-61 During the period from January 1, 2025 to April 10, 2025, the Company sold 290,618shares of Common Stock of the Company pursuant to the New Keystone Purchase Agreement for net proceeds of $ 1,227,242. On February 5, 2025, the Company announced the pricing of a reasonable best efforts public offering (the “Offering”), with participation from a member of the Company’s board of directors and a single institutional investor, for the purchase and sale of (i) 2,551,020shares of its common stock, par value $ 0